Small Ball Biotech
Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as...
Gespeichert in:
Veröffentlicht in: | Forbes 2021-02, Vol.204 (1), p.33 |
---|---|
1. Verfasser: | |
Format: | Magazinearticle |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 33 |
container_title | Forbes |
container_volume | 204 |
creator | Knapp, Alex |
description | Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says. |
format | Magazinearticle |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2492705418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666098532</galeid><sourcerecordid>A666098532</sourcerecordid><originalsourceid>FETCH-LOGICAL-g134t-13965538d67d0f1b2211b115254893b23e26a9d6a38c7c787cd4762a684493b33</originalsourceid><addsrcrecordid>eNotj01LxDAYhIMoWFcv_gJP4iWQ982br-O6-AULHtRzSNNsrWRbNSn48y2uc5g5zMPAHLEGtXAciNQxa4QAxbUDOmVnpXyIRUDYsMuXfcj56vbPhqmm-H7OTnYhl3Txnyv2dn_3unnk2-eHp816y3uQVDlIp5WSttOmEztoEQFaAIWKrJMtyoQ6uE4HaaOJxprYkdEYtCVaeilX7Oaw-_k9fc2pVL8fSkw5hzFNc_FIDo1QBHZBrw9oH3Lywxinsaaf2oe5FO_XWi9PrZIofwEXg0G0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>2492705418</pqid></control><display><type>magazinearticle</type><title>Small Ball Biotech</title><source>EBSCOhost Business Source Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Knapp, Alex</creator><creatorcontrib>Knapp, Alex</creatorcontrib><description>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</description><identifier>ISSN: 0015-6914</identifier><identifier>EISSN: 2609-1445</identifier><language>eng</language><publisher>New York: Forbes LLC</publisher><subject>Antibodies ; Biotechnology industry ; Businesspeople ; Chief executive officers ; Entrepreneurship ; Evaluation ; Hansen, Carl ; Immune system ; Officials and employees ; R&D ; Research & development</subject><ispartof>Forbes, 2021-02, Vol.204 (1), p.33</ispartof><rights>COPYRIGHT 2021 Forbes LLC</rights><rights>Copyright Forbes Feb/Mar 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784</link.rule.ids></links><search><creatorcontrib>Knapp, Alex</creatorcontrib><title>Small Ball Biotech</title><title>Forbes</title><description>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</description><subject>Antibodies</subject><subject>Biotechnology industry</subject><subject>Businesspeople</subject><subject>Chief executive officers</subject><subject>Entrepreneurship</subject><subject>Evaluation</subject><subject>Hansen, Carl</subject><subject>Immune system</subject><subject>Officials and employees</subject><subject>R&D</subject><subject>Research & development</subject><issn>0015-6914</issn><issn>2609-1445</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2021</creationdate><recordtype>magazinearticle</recordtype><sourceid/><recordid>eNotj01LxDAYhIMoWFcv_gJP4iWQ982br-O6-AULHtRzSNNsrWRbNSn48y2uc5g5zMPAHLEGtXAciNQxa4QAxbUDOmVnpXyIRUDYsMuXfcj56vbPhqmm-H7OTnYhl3Txnyv2dn_3unnk2-eHp816y3uQVDlIp5WSttOmEztoEQFaAIWKrJMtyoQ6uE4HaaOJxprYkdEYtCVaeilX7Oaw-_k9fc2pVL8fSkw5hzFNc_FIDo1QBHZBrw9oH3Lywxinsaaf2oe5FO_XWi9PrZIofwEXg0G0</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Knapp, Alex</creator><general>Forbes LLC</general><general>Forbes</general><scope/></search><sort><creationdate>20210201</creationdate><title>Small Ball Biotech</title><author>Knapp, Alex</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g134t-13965538d67d0f1b2211b115254893b23e26a9d6a38c7c787cd4762a684493b33</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Biotechnology industry</topic><topic>Businesspeople</topic><topic>Chief executive officers</topic><topic>Entrepreneurship</topic><topic>Evaluation</topic><topic>Hansen, Carl</topic><topic>Immune system</topic><topic>Officials and employees</topic><topic>R&D</topic><topic>Research & development</topic><toplevel>online_resources</toplevel><creatorcontrib>Knapp, Alex</creatorcontrib><jtitle>Forbes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knapp, Alex</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small Ball Biotech</atitle><jtitle>Forbes</jtitle><date>2021-02-01</date><risdate>2021</risdate><volume>204</volume><issue>1</issue><spage>33</spage><pages>33-</pages><issn>0015-6914</issn><eissn>2609-1445</eissn><abstract>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</abstract><cop>New York</cop><pub>Forbes LLC</pub><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0015-6914 |
ispartof | Forbes, 2021-02, Vol.204 (1), p.33 |
issn | 0015-6914 2609-1445 |
language | eng |
recordid | cdi_proquest_miscellaneous_2492705418 |
source | EBSCOhost Business Source Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Antibodies Biotechnology industry Businesspeople Chief executive officers Entrepreneurship Evaluation Hansen, Carl Immune system Officials and employees R&D Research & development |
title | Small Ball Biotech |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T06%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20Ball%20Biotech&rft.jtitle=Forbes&rft.au=Knapp,%20Alex&rft.date=2021-02-01&rft.volume=204&rft.issue=1&rft.spage=33&rft.pages=33-&rft.issn=0015-6914&rft.eissn=2609-1445&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA666098532%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2492705418&rft_id=info:pmid/&rft_galeid=A666098532&rfr_iscdi=true |